Fangchinoline induces gallbladder cancer cell apoptosis by suppressing PI3K/Akt/XIAP axis.

Gallbladder cancer (GBC) is the most common biliary tract malignancy with a dismal prognosis. The development of new drugs may help to improve prognosis. This study found that fangchinoline, a bisbenzylisoquinoline alkaloids, inhibited the proliferation and clone formation of GBC cells in a dose-dependent manner. Moreover, Hoechst staining, TUNEL assays, and flow cytometry demonstrated that fangchinoline effectively induced apoptosis in GBC cells. Further studies found that an anti-apoptotic pathway, the PI3K/Akt/XIAP axis, was significantly inhibited in GBC cells after treating with fangchinoline. Finally, we confirmed that fangchinoline restrained xenograft tumor growth in vivo. Our findings indicate that fangchinoline can be considered a potential drug for GBC treatment.

Introduction

Gallbladder cancer (GBC) is a highly lethal hepatobiliary malignancy originating from gallbladder mucosa and is the most common biliary tract tumor [1]. Notably, due to a lack of specific early detection methods and the asymptomatic nature of an initial stage, 40%-70% of GBC patients are diagnosed at an advanced stage with metastatic lesions [2], contributing to disease’s dismal prognosis. According to National Cancer Data Base of the American College of Surgeons, the 5-year survival rates for GBC patients are separately 4% and 2% for stage IVa and stage IVb [2]. Consequently, the treatment of gallbladder cancer becomes extremely critical.

Surgical resection is the most effective treatment for GBC [3]. Unfortunately, many patients are always diagnosed at advanced stages, when surgery is no longer a possibility. While the standard first-line chemotherapeutic regimen of gemcitabine combined with cisplatin is required, its efficacy remains unsatisfactory [4]. Although immunosuppressants and molecularly targeted drugs have recently garnered increased attention [5, 6], they are expensive, and their curative effect appears to be ambiguous. It is necessary to identify an effective drug that can improve prognosis and reduce economic expenditure associated with GBC.

Fangchinoline (FAN), a bisbenzylisoquinoline alkaloid, is one of the main bioactive ingredients of Stephania tetrandra S. Moore and has been illustrated to hold potent pharmacological effects such as anti-inflammatory, antioxidant, and neuroprotective properties [7-9]. Notably, what makes this compound stand out is its anti-tumor activity in various cancers. Numerous researchers have recently discovered that fangchinoline can help alleviate the malignant phenotype of various tumors, including breast and lung cancer [10, 11]. Moreover, fangchinoline induces apoptosis in tumor cells mediated by various signaling pathways [11-13]. Several studies revealed that fangchinoline is regarded as a potential anticancer drug. However, no effective research regarding fangchinoline function on GBC has been conducted previously.

This study aimed to evaluate the role of fangchinoline on GBC cell lines GBC-SD and NOZ. Furthermore, the drug’s effectiveness was demonstrated in vivo through tumor formation tests, and finally, the drug’s possible underlying mechanism of action was clarified.

Materials and methods

Reagents

Fangchinoline (cas. no. 436-77-1) was purchased from Biopurify Phytochemicals Ltd. (Chengdu, China). SC79 (cat. no. SF2730) was obtained from Beyotime Institute of Biotechnology (Nanjing, China). Primary antibodies against FAK (cat. no. 3285), Phospho-FAK (Tyr576/577, cat. no. 3281), Src (cat. no. 2123), Phospho-Src (Tyr527, cat. no. 2105), PI3K (cat. no. 4249), Phospho-PI3K p85 (Tyr458)/p55 (Tyr199) (cat. no. 4228), Phospho-Akt (Ser473, cat. no. 4060), mTOR (cat. no. 2972), Phospho-mTOR (Ser2448) (cat. no. 5536), XIAP (cat. no. 2045), and β-Actin (cat. no. 3700) were purchased from Cell Signaling Technology (Boston, MA, USA). Primary antibodies against Akt (cat. no. 10176-2-AP) were purchased from Proteintech (Wuhan, China). HRP-conjugated secondary antibodies (cat. nos. A0216 and A0208), PMSF (cat. no. ST506), Enhanced BCA Protein Assay kit (cat. no. P0010), RIPA Lysis Buffer (cat. no. P0013B), Hoechst Staining Kit (cat. no. C0003), One Step TUNEL Apoptosis Assay Kit (cat. no. C1089) were obtained from Beyotime Institute of Biotechnology. CCK-8 was obtained from MCE (Monmouth Junction, NJ, USA). Annexin V Apoptosis Detection Kit was gained from BD Biosciences (Franklin Lakes, NJ, USA).

Cell culture

The human GBC cell line GBC-SD was acquired from the Chinese Academy of Science Shanghai Branch Cell Bank (Shanghai, China). NOZ cell line was purchased from the HAKATA Cell Bank of the Shanghai Chuanqiu Biotechnology Co., LTD (Shanghai, China). GBC-SD cells were cultured in RPMI-1640 and NOZ cells were cultured in DMEM medium with 10% fetal bovine serum (FBS) in the incubator at an atmosphere of 37°C containing 5% CO2. Fangchinoline was dissolved in DMSO and diluted in medium (with the same level of DMSO in the control group) to a final value of DMSO<0.1%.

Cell viability assays

Cells were plated in 96-well plates at a density of 4×103 cells per well and incubated in medium containing different concentrations of fangchinoline for 48 h. The plates were incubated at 37°C for another 2 h after one-tenth volume of CCK8 reagent added to each well. Cell density was determined by measuring the absorbance at 450 nm with a microplate reader.

Colony formation assays

After cell counting, GBC cells were seeded in 6-well plates at 5 × 102 cells per well and cultured overnight. The GBC cells were treated with different concentrations of fangchinoline, while the culture medium containing DMSO was used as the control group. After 14 days, the cells were fixed with 4% paraformaldehyde and then stained with 0.01% crystal violet.

Cell apoptosis analysis

GBC-SD cells were incubated with different concentrations of fangchinoline for 48 h. After treating with EDTA-free trypsin, the cells were collected and resuspended in 1×Binding Buffer sufficiently. The resuspended cells were stained with Annexin V-FITC and propidium iodide (PI) (Becton-Dickinson, Franklin, NJ, USA) following the manufacturer’s instructions. The apoptosis rate was determined by flow cytometry (Beckman Coulter, Fullerton, CA, USA).

Hoechst 33258 staining

GBC cells were seeded in 24-well plates at 2×104 cells per well and cultured overnight. Then, the GBC cells were cultured with different concentrations of fangchinoline for further 48 h. The concentrated nuclei were observed under a Nikon fluorescence microscope (Tokyo, Japan) according to the instructions of the apoptosis staining kit (cat. no. C0003; Beyotime).

TUNEL assays

Briefly, GBC cells were plated in 96-well plates. The culture condition was changed to the serum-free medium containing DMSO or fanchinoline when the density of cells was about 60%. After 48 h, the cells were fixed, permeated, and then stained with a TUNEL kit (cat. no. C1089; Beyotime) according to manufacturer’s instructions.

Treating cells with SC79

The GBC cells were seeded in 6-well plates at about 40% densities and cultured overnight. After starving with serum-free medium for 1 h, the GBC cells were treated with medium with 5% FBS plus 4μg/ml SC79 for 30 min. After incubated with different concentrations of fangchinoline for 48 h, the cells were harvested for western blot analysis.

Western blot analysis

Total protein extracted from GBC cells was obtained with RIPA lysis (cat. no. P0013B; Beyotime) buffer containing 1% PMSF (cat. no. ST506; Beyotime). After quantified by BCA kit (cat. no. P0010; Beyotime), 30 μg protein sample was electrophoresed on a 10% SDS–PAGE gel and transferred onto a polyvinylidene fluoride membrane. The membrane was blocked and incubated with a primary antibody, followed by incubation with a horseradish peroxidase-conjugated secondary antibody (cat. nos. A0216 and A0208; Beyotime). Immunoreactive bands were visualized using a chemiluminescence solution (Millipore, Temecula, CA, USA), β-Actin was used as the endogenous control.

Xenograft formation assays

The six-week-old male athymic nude mice were purchased from SLAC Laboratory Animal Company (Shanghai, China). To establish a tumor xenograft model, the backs of all nude mice were injected subcutaneously with 200μl 0.9% normal saline containing GBC-SD cells (2×106). After a week, the nude mice with tumor xenograft were randomly divided into two groups (n = 7). The experimental group was intraperitoneally injected with fangchinoline (5mg/kg, dissolved in 20% DMSO) while the control group was injected with 0.9% normal saline (20% DMSO) every other day for 3 weeks. To minimize the suffering, all mice were sacrificed via cervical dislocation under sevoflurane inhalation anesthesia after four weeks, the death of the mice was confirmed by examining the cessation of vital signs. The weight and volume of the tumors were measured and the tumor volume was calculated by the following formula: volume = length×width2/2. All the mice had ad libitum access to food and water and were maintained at an atmosphere of 20–25°C and 50–60% humidity under a cycle of 12 h light/dark. All procedures were approved by the Ethics Committee of Shaoxing People’s Hospital and conformed to the ARRIVE guidelines 2.0 published in PLOS Biology.

Statistical analysis

All experiments were repeated at least three times, and data are presented as the means ± SD. Student’s t-test was used to determine statistical significance between two groups. One-way ANOVA followed by the Tukey–Kramer adjustment was used to examine differences among multiple groups. All statistical analyses were conducted using SPSS v21.0 (IBM, Armonk, NY, USA), and P < 0.05 was considered statistically significant.

Results

Fangchinoline inhibits the proliferation of GBC cells

CCK8 assays were used to determine the effect of fangchinoline on the proliferation of GBC cells. The concentration-dependent cell viability curves revealed that fangchinoline inhibited the proliferation of GBC-SD and NOZ cells in a dose-dependent manner (Fig 1A). Additionally, GBC-SD cells were more sensitive to fangchinoline compared with NOZ cells. Colony formation assay also revealed that fangchinoline significantly inhibited the colony-forming ability of GBC cells, compared with the control group (Fig 1B).

Fig 1

Fangchinoline suppresses the proliferation of GBC cells.

(A) The cell viability curves detected using CCK8 assays after treating GBC-SD and NOZ cells with different fangchinoline concentrations. (B) The colony formation ability of GBC-SD and NOZ cells treated with different fangchinoline concentrations. Data are presented as mean ± SD. *P<0.05. **P<0.01. ***P<0.001, compared with the DMSO group.

Fangchinoline induces the apoptosis of GBC cells

Various anticancer drugs could inhibit proliferation by inducing apoptosis of cancer cells as the more common mechanism [14-16]. To examine whether fangchinoline induces tumor apoptosis, Hoechst staining, TUNEL assays, and Annexin V/PI apoptosis assays were performed. Hoechst staining revealed that after fangchinoline treatment, more GBC-SD and NOZ cells had a concentrated nuclear population (Fig 2A). TUNEL staining also revealed that the fangchinoline-treated group had more TUNEL-positive cells than the control group (Fig 2B). Moreover, Annexin V/PI assays confirmed that fangchinoline-treated GBC-SD cells had a higher proportion of apoptotic cells and a lower proportion of live cells than the untreated group (Fig 2C). Overall, sufficient data demonstrated that fangchinoline induced apoptosis of GBC cells.

Fig 2

Fangchinoline induces the apoptosis of GBC cells.

(A) Hoechst 33258 staining of GBC cells treated with fangchinoline. (B) TUNEL assay of the apoptosis effect of GBC cells with high fangchinoline concentration. (C) Annexin V/ PI apoptosis assay of GBC-SD. Annexin V (+)/PI (−) or Annexin V (−)/PI (+) were considered as apoptotic cells, Annexin V (−)/PI (−) cells were alive, and Annexin V (+)/PI (+) cells were necrotic.

Fangchinoline inhibits the PI3K/Akt/XIAP axis

PI3K/Akt is an important cancer-related pathway that influences cancer cell apoptosis and survival [17, 18]. Western blot was conducted to investigate the impact of fangchinoline on PI3K/Akt pathway in GBC-SD and NOZ cells. The results indicated that fangchinoline could inhibit PI3K and Akt expression (Fig 3A). XIAP is a PI3K/Akt pathway downstream protein that inhibits cell apoptosis [19, 20]. Additionally, we discovered that XIAP was dose-dependently downregulated (Fig 3A).

Fig 3

Fangchinoline inhibits the PI3K/Akt/XIAP signaling axis.

(A) Results of FAK, p-FAK (Tyr576/577), Src, p-Src (Tyr527), PI3K, p-PI3K (Tyr458/Tyr199), AKT, p-AKT (Ser473), mTOR, p-mTOR (Ser2448), and XIAP relative protein expression using Western blot. (B) GBC cells were incubated with p-Akt activator SC-79 alone or combined with fangchinoline before lysis for Western blot. Data are presented as mean ± SD. *P<0.05. **P<0.01 and ***P<0.001, compared with the DMSO group.

To further confirm the interaction between p-Akt and XIAP, an agonist of Akt pathway, SC79, was employed to upregulate p-Akt expression. The expression level of XIAP was markedly upregulated, consistent with p-Akt after treating with SC79 (Fig 3B). Interestingly, fangchinoline treatment effectively reversed SC79-induced increases in XIAP and p-Akt expression (Fig 3B). It indicated that inhibiting PI3K/Akt/XIAP axis was the potential mechanism of how fangchinoline induced GBC cell apoptosis.

Fangchinoline suppresses the oncogenesis of GBC-SD cells in vivo

A xenograft formation assay in nude mice was performed to further evaluate fangchinoline’s potential efficacy in vivo. The results revealed that the weight and volume of tumors in the fangchinoline-treated group were decreased compared with those in the control group (Fig 4; Table 1). Moreover, none of tumor-bearing mice died during the experiment, demonstrating the feasibility of fangchinoline effectively inhibiting tumor progression. It indicated that fangchinoline effectively suppressed the oncogenesis of GBC-SD cells in vivo.

Fig 4

Fangchinoline suppresses the oncogenesis of GBC-SD cells in vivo.

(A) The photograph of nude mice and xenograft tumors. (B) The volume and weight of xenograft tumors were measured. **P < 0.01, compared with the DMSO group.

Table 1

Tumor growth in nude mice.

Group	n	Volume (mm3)	Weight (g)
DMSO	7	758.14±293.18†	1.07±0.26
Fangchinoline	7	256.89±250.61	0.50±0.24

† Mean.

± Standard Deviation.

Discussion

Apoptosis, also known as programmed cell death, is a crucial self-stabilizing mechanism in multicellular organisms [21]. It eliminates incompatible cells from the body to maintain a healthy balance [22-24]. Numerous studies indicate that diseases such as cancer may be linked to underlying defects in apoptosis pathways which keep cells alive that should die [25, 26].

Fangchinoline has been shown to have anti-tumor effects, inhibiting the formation and development of multiple tumor cells. Previous study reported that fangchinoline promotes apoptosis in prostate cancer cells by suppressing the proteasome β1 subunit [27]. Similarly, fangchinoline has been demonstrated to promote apoptosis in human pancreatic cancer cells [12], breast cancer cells [10], and bladder cancer cells [28]. Although the mechanism of action is various, these studies indicated that fangchinoline functions as an anti-tumor drug in multiple tumor types by inducing apoptosis. Through various experimental methods, we demonstrated here that fangchinoline also effectively induces apoptosis in GBC cells.

Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase lacking a transmembrane region [29]. Numerous studies have established that it is critical in the progression of tumors toward malignant and invasive phenotypes [30, 31]. Fangchinoline has been demonstrated to inhibit FAK-related signaling pathway. After activation, FAK can be tightly bound to Src family genes via SH2 domain, activating downstream to control cell growth [32, 33]. Additionally, we examined FAK-related signaling pathway in this study. However, we discovered that fangchinoline had no significant effect on FAK expression. Therefore, PI3K/Akt signaling pathway associated with FAK attracted our attention.

PI3K, a member of lipid kinase family, phosphorylates the 3’-OH group of inositol ring to generate the second messenger PIP3 in the plasma membrane [17]. PI3K successfully recruits a subset of signaling proteins such as Akt with pleckstrin homology (PH) domain to mediate cell proliferation and apoptosis by virtue of PIP3 [34, 35]. In the whole cascade, Akt is considered the central mediator of PI3K/Akt signaling pathway. Fangchinoline can promote the apoptosis of human glioblastoma cells by inhibiting Bax and caspase9 expression through Akt pathway [36]. Similar mechanisms have been observed in breast cancer cells [37] and leukemia cells [38]. Consistent with previous findings, we discovered that fangchinoline could significantly downregulate the expression of PI3K, Akt, and associated phosphorylated proteins. In osteosarcoma, fangchinoline suppresses the migration and invasion of cells through the PI3K/Akt pathway [39]. And apoptosis is induced through activating downstream caspase which is different from our results. In our experiments, fangchinoline had no significant effect on metastasis of gallbladder cancer cells. XIAP is an intracellular anti-apoptotic protein in GBC-SD and NOZ cells. The expression of XIAP was significantly downregulated after drug treatment. A study reported that Akt phosphorylation could inhibit XIAP ubiquitination, reduce its degradation, and partially reverse cisplatin-induced apoptosis of ovarian cancer epithelial cells [40], indicating that XIAP can be an Akt substrate. Our experiments unambiguously demonstrated an interaction between p-Akt and XIAP. Therefore, it is reasonable to conclude that fangchinoline can promote the apoptosis of GBC cells by inhibiting XIAP expression via PI3K/Akt pathway.

In summary, this study mainly probed the effects of fangchinoline on GBC-SD and NOZ gallbladder cancer cells. The results demonstrated that fangchinoline induced the apoptosis of GBC cells by regulating PI3K/Akt/XIAP signaling axis.

(ZIP)

Click here for additional data file.

18 Jan 2022

15 Feb 2022

Responses to the comments of Reviewer #1

I consider that this article contains important results on the effect of fangchinoline (a bisbenzylisoquinoline alkaloid) wher the authors demonstrated the inhibition of the proliferation and clone formation of GBC cells in a dose-dependent manner and the induction of apoptosis in GBC cells. Authors also showed that fangchinoline acts in vivo by restraining xenograft tumor growth on six-week-old male athymic nude mice.

The document is written correctly and there is a good review of the literature on the subject developed, in addition to meeting the criteria of the journal, so I consider it can be published without problem.

Response: Thank you for the Reviewer’s positive comments.

Responses to the comments of Reviewer #2

1. The manucript Fangchinoline induces gallbladder cancer cell apoptosis by suppressing PI3K/Akt/XIAP axis lacks the selection of this alkaloid as an inhibitor of PI3K/Akt/XIAP? why not PI3K/Akt/mTOR?

Response: As the comments of Reviewer, we have examined the PI3K/Akt/mTOR axis and provided the results in the revised manuscript (Fig3). Unfortunately, the difference of p-mTOR was not significant with or without Fangchinoline treatment (Fig3). On the other hand, the relationship between XIAP and Akt had been further confirmed by an Akt activator, SC79 (Fig3).

2. Also, the rationality is required to show the anti-cancer activity of Fangchinoline. The author should use positive control in all the assays.

Response: The suggestion from the reviewer is helpful. However, the aim of our study is to determine whether Fangchinoline effectively inhibits GBC proliferation in vivo and in vitro, rather than to compare it with other anti-cancer drugs. Similar research strategy has been used by abundant studies. [1-5]

3. Fangchinoline suppresses the proliferation, invasion and tumorigenesis of human osteosarcoma cells through the inhibition of PI3K and downstream signaling pathways is reported IJMM 2017. So better the author compare some results with the published mode of action of this alkaloid and resubmit.

Response: As the comments of Reviewer, the comparison of relevant conclusions has been added to our revised manuscript.

Responses to the comments of Editor

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming.

Response: As the comments of Editor, we have mad revisions in our revised manuscript, including style and file naming.

2. To comply with PLOS ONE submissions requirements, in your Methods section, please provide additional information on the animal research and ensure you have included details on (1) methods of sacrifice, (2) methods of anesthesia and/or analgesia, (3) efforts to alleviate suffering, (4) number of animals used in the study.

Response: As the comments of Editor, the additional information on the animal research has been added into the section of Xenograft formations assays.

3. Thank you for stating the following in the Acknowledgments Section of your manuscript:

“The work was sponsored by Zhejiang Provincial Natural Science Foundation of China under grant no. LY19H160016, National Natural Science Foundation of China (NSFC) no. 81602044, Zhejiang Provincial Medical and Health Science and Technology Project under grant no. 2019ZD057.”

Please note that funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

“This work was supported by National Natural Science Foundation of China (NSFC) no. 81602044 and Zhejiang Provincial Natural Science Foundation of China under grant no. LY19H160016. Dr. Jianhua Yu received these funding and was responsible for the decision to publish this manuscript.

This work was also supported by Zhejiang Provincial Medical and Health Science and Technology Project under grant no. 2019ZD057. Dr. Baochun Lu received the funding and was responsible for data collection of this manuscript.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

Response: As the comments of Editor, the funding-related text in manuscript has been removed. Meanwhile, we have updated the funding information as the comments of Editor:

“This work was supported by Zhejiang Provincial Natural Science Foundation of China under grant no. LY22H160008, LY19H160016, National Natural Science Foundation of China (NSFC) no. 81602044, Zhejiang Provincial Medical and Health Science and Technology Project under grant no. 2022RC080 and 2020RC127. Dr. Jianhua Yu received these funding and was responsible for the decision to publish this manuscript.

This work was also supported by Zhejiang Provincial Natural Science Foundation of China under grant no. LBY22H030001 and Zhejiang Provincial Medical and Health Science and Technology Project under grant no. 2019ZD057. Dr. Baochun Lu received the funding and was responsible for data collection of this manuscript.”

Thanks to the Editors for changing the online submission form on our behalf.

4. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found.

Response: As the comments of Editor, the minimal data set underlying results has been added into our supplementary materials. All relevant data now are within the revised manuscript and its Supporting information files.

5. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files.

Response: As the comments of Editor, the original uncropped and unadjusted images underlying all blot or gel results have been uploaded and named ‘S1_raw_images’.

6. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Response: We have reviewed our reference list as the Reviewer suggested and there are no papers have been retracted. It’s worth noting that a new papers[6] was cited in our Discussion section.

Submitted filename: Response to Reviewers.doc

Click here for additional data file.

28 Mar 2022

Fangchinoline induces gallbladder cancer cell apoptosis by suppressing PI3K/Akt/XIAP axis

PONE-D-21-34482R1

Dear Dr. Yu,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Irina V. Balalaeva, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

12 Apr 2022

PONE-D-21-34482R1

Fangchinoline induces gallbladder cancer cell apoptosis by suppressing PI3K/Akt/XIAP axis

Dear Dr. Yu:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Irina V. Balalaeva

Academic Editor

PLOS ONE